S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in

Cryo-Cell International Stock Forecast, Price & News

-0.10 (-1.19 %)
(As of 01/22/2021 12:00 AM ET)
Today's Range
Now: $8.30
50-Day Range
MA: $7.60
52-Week Range
Now: $8.30
Volume20,950 shs
Average Volume14,499 shs
Market Capitalization$62.63 million
P/E Ratio20.75
Dividend YieldN/A
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, kidney, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was founded in 1989 and is headquartered in Oldsmar, Florida.


Overall MarketRank

1.21 out of 5 stars

Medical Sector

800th out of 1,925 stocks

Miscellaneous Health & Allied Services, Not Elsewhere Classified Industry

11th out of 25 stocks

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Miscellaneous health & allied services, not elsewhere classified
Current SymbolOTCMKTS:CCEL



Sales & Book Value

Annual Sales$31.80 million
Cash Flow$0.38 per share
Book Value($0.89) per share


Net Income$2.29 million


Market Cap$62.63 million
Next Earnings Date2/25/2021 (Estimated)
OptionableNot Optionable
-0.10 (-1.19 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CCEL News and Ratings via Email

Sign-up to receive the latest news and ratings for CCEL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Cryo-Cell International (OTCMKTS:CCEL) Frequently Asked Questions

How has Cryo-Cell International's stock been impacted by COVID-19 (Coronavirus)?

Cryo-Cell International's stock was trading at $7.20 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CCEL shares have increased by 15.3% and is now trading at $8.30.
View which stocks have been most impacted by COVID-19

What stocks does MarketBeat like better than Cryo-Cell International?

Wall Street analysts have given Cryo-Cell International a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cryo-Cell International wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Cryo-Cell International's next earnings date?

Cryo-Cell International is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Cryo-Cell International

How were Cryo-Cell International's earnings last quarter?

Cryo-Cell International, Inc. (OTCMKTS:CCEL) released its earnings results on Tuesday, October, 15th. The company reported $0.13 earnings per share (EPS) for the quarter. The company had revenue of $8.20 million for the quarter. Cryo-Cell International had a negative return on equity of 58.74% and a net margin of 10.39%.
View Cryo-Cell International's earnings history

Who are some of Cryo-Cell International's key competitors?

What other stocks do shareholders of Cryo-Cell International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cryo-Cell International investors own include NVIDIA (NVDA), Overstock.com (OSTK), Avid Technology (AVID), The Boeing (BA), Enphase Energy (ENPH), OPKO Health (OPK), Riot Blockchain (RIOT), Aldeyra Therapeutics (ALDX), Alimera Sciences (ALIM) and Allena Pharmaceuticals (ALNA).

Who are Cryo-Cell International's key executives?

Cryo-Cell International's management team includes the following people:
  • Mr. David I. Portnoy, Chairman & Co-CEO (Age 57, Pay $652.09k)
  • Mr. Mark L. Portnoy, Co-Chief Exec. Officer (Age 56, Pay $519k)
  • Ms. Jill M. Taymans, CFO & VP of Fin. (Age 50, Pay $201.5k)
  • Mr. Oleg Mikulinsky, Chief Information Officer (Age 47, Pay $258.33k)
  • Dr. Merri Buff Mair, Medical Director & Member of Medical & Scientific Team

What is Cryo-Cell International's stock symbol?

Cryo-Cell International trades on the OTCMKTS under the ticker symbol "CCEL."

How do I buy shares of Cryo-Cell International?

Shares of CCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cryo-Cell International's stock price today?

One share of CCEL stock can currently be purchased for approximately $8.30.

How big of a company is Cryo-Cell International?

Cryo-Cell International has a market capitalization of $62.63 million and generates $31.80 million in revenue each year. Cryo-Cell International employs 87 workers across the globe.

What is Cryo-Cell International's official website?

The official website for Cryo-Cell International is www.cryo-cell.com.

How can I contact Cryo-Cell International?

Cryo-Cell International's mailing address is 700 Brooker Creek Boulevard Suite 1800, Oldsmar FL, 34677. The company can be reached via phone at 813-749-2100.

This page was last updated on 1/23/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.